AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: AstraZeneca is currently conducting a clinical study titled ‘Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation).’ The primary aim is to assess the safety and effectiveness of Ondexxya, focusing on detecting unknown adverse reactions and understanding factors affecting its safety and efficacy.
Intervention/Treatment: The study investigates Ondexxya, an intravenous injection used to reverse anticoagulation effects in patients. It aims to ensure the drug’s safety and effectiveness in real-world settings.
Study Design: This is an observational cohort study with a prospective time perspective. It focuses on collecting data on the safety and effectiveness of Ondexxya under actual use conditions without any intervention model or masking.
Study Timeline: The study began on June 2, 2022, with the last update submitted on July 8, 2025. These dates are crucial as they indicate the study’s progress and ongoing data collection efforts.
Market Implications: The ongoing study of Ondexxya could influence AstraZeneca’s stock performance by potentially enhancing investor confidence if the results demonstrate safety and effectiveness. This could also impact competitors in the anticoagulation reversal market, highlighting AstraZeneca’s commitment to drug safety.
The study is currently recruiting, with further details available on the ClinicalTrials portal.